key: cord-1005236-y3yutzb8
authors: Puxkandl, Viktoria; Bangerl, Theresa; Hanfstingl, Kathrin; Guenova, Emmanuella; Hoetzenecker, Wolfram; Altrichter, Sabine
title: Second-dose COVID-19 vaccines are well tolerated in patients with allergic reactions to the first dose – a single center experience
date: 2022-05-20
journal: World Allergy Organ J
DOI: 10.1016/j.waojou.2022.100654
sha: 1b9d41144736ca3eb19351ac86c2cf801cfe06d4
doc_id: 1005236
cord_uid: y3yutzb8

COVID-19 vaccines contain additives such as Polyethylenglycol-2000 (PEG2000; mRNA vaccines) or Polysorbat 80 (vector vaccines), which have been described previously as culprits for anaphylactic events. This retrospective study included 46 individuals, who were referred to XXX with suspected allergic reactions to the first COVID-19 vaccine dose with either mRNA or vector-based vaccines. Patients underwent detailed anamnesis, clinical examination and in most cases skin prick testing using pure additive substances (PEG – different molecular weights, Polysorbate 80). Out of 46, 7 patients’ reactions were classified as possibly anaphylactic and graded according to Ring & Messmer. Forty patients out of 46 were assessed with skin prick tests for potential allergens in COVID-19 vaccines. Only one patient showed an immediate positive prick test to PEG2000. Second-dose vaccination with mRNA or vector-based vaccines were tolerated well in all patients, including the individual with a positive skin prick test against PEG2000. The currently available COVID-19 vaccines have an overall low allergic potential and may be administered safely in patients with suspected allergic reactions to the first dose.

Wolfram Hoetzenecker has conducted studies for/ was advisor for/ was speaker for Novartis, Eli Lilly, Bencard, ALK, Leo Pharma, Kyowa Kirin, Takeda, Sanofi-Aventis and AbbVie.

The other authors state no conflict of interests.

Ethics approval and consent to participate:

Retrospective data analysis. Ethical approval was seeked at the ethical committee of the Kepler University Hospital (EK Nr. 1304/2021).

Availability of data and materials:

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

All authors consent the publication of the manuscript.

VP was in charge for data collection, data management and drafting of the manuscript.

TB was involved in patient care and data entry.

KH was involved in patient care and data entry.

EG was involved in critical proof reading of the manuscript. WH supervised the project and was in charge for critical proof reading of the manuscript.

SA was head of the patient care and patient vaccinations and was involved in manuscript preparation.

All authors read and approved the final manuscript. 

Patients frequently report reactions after COVID-19 vaccinations, but only about 15% of these qualify as 7 possible allergic reactions. Prick-Tests using pure vaccine additives resulted rarely in positive results and 8 all revaccinated patients tolerated a second dose without anaphylaxis. 

The currently available COVID-19 vaccines have an overall low allergic potential and may be 25 administered safely in patients with suspected allergic reactions to the first dose. 

This retrospective single-centered study included 46 patients that were referred to XXX with a history of potential allergic reaction to the first COVID-19 vaccination. (Supplemental table 1) 

Of these patients, 39 had histories of unspecific immediate reactions (most likely non-allergic reactions 50 e.g. hypertension, head-ace or unspecific reactions such as vertigo, tingling or pricking sensations, etc.) or 51 delayed reactions (e.g., intense local reactions, flush, nausea or urticaria more than one day after 52 vaccination). Only seven (15%) patients displayed a history consistent with a possible anaphylactic 53 reaction according to Ring and Messmer´s (5) (Grade I: 2x, Grade II: 3x; Grade III: 1x, see Table 1 ). These 54 patients reported immediate treatment including antihistamines, corticosteroids and in one case 55 adrenaline (Grade III reaction). None of them needed intensive care treatment. Serum tryptase level 56 determination of these events was not performed.

We performed SPT in 40/46 patients with the culprit allergens as listed in Supplemental Table 2 . All 59 patients were tested with all substances. In 37/40 cases, immediate type sensitization to PEG and/or prior SPT (medical history ruled out risk of anaphylaxis or inability to test because of systemic anti-allergic consenting of the patients. (see Figure 1 ) Importantly, we did not observe any anaphylactic reaction after Table 1 ). Premedication with single or double dose of second-generation antihistamines 30-60 minutes 69 prior to the vaccination was given in 17 cases.

Of the remaining 24 patients, around two thirds received the 2 nd vaccine in a peripheral setting 

In all cases, except one, allergy to PEG-2000 and Polysorbate-80 was ruled out and second dose vaccination 80 was well tolerated in all patients. Other authors reported positive results more frequently, but they used 81 complex medications with different ingredients (4). Accordingly, we think that SPT with pure PEG and 82 Polysorbate solutions could be of value in selected cases of patients (see also 6). Since the vaccines are now 83 abundantly available they could also be used for skin prick testing, as alternative. If the use of these is 84 superior to testing of the additives alone is currently not known and there is the possibility of a delayed 85 skin reaction as immune response to virus particles or adjuvances (7) that do not reflect allergic reactions. Vector,

Corona Virus Disease

We thank the assistants of the allergy center for their excellent patient care. 

J o u r n a l P r e -p r o o f + Reaction to SPT -n = 1 + Reaction to SPTn = 0 * anamnestical no evidence for allergic reaction in context with the vaccination ** two invalid SPT included *** including the Patient with reaction to SPT # until timepoint of assessment or lost to follow up (incl. possible external vaccination) abbreviations: SPT skin-prick test.